Delivery Order SPE2DB24D1205-SPE2DB25FCXNR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,791.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injectors on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999.9 million through December 2026. The contract involves no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a ceiling value of $10,513.23. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made without a...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a $5,593.98 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of August 7, 2025, and performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a tirzepatide-based medication used for weight management,...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors on August 18, 2025, with a ceiling value of $3,291.68 and ultimate completion date of August 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors at a fixed price of $8,232.97, with completion scheduled for September 8, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,232.68 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen injectors on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed price contract was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXNRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,118.02 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on June 9, 2025, with an ultimate completion date of June 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This contract supports the pharmaceutical supply needs of the Defense Health Agency and other federal healthcare systems, with AmerisourceBergen serving as a critical prime vendor for military medical procurement. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, reflecting the company's broad portfolio of specialty medications and brand-name pharmaceuticals supplied through the DLA Medical Supply Chain. The award demonstrates AmerisourceBergen's continued capability to fulfill federal medical supply requirements through competitive procurement processes, contributing to the broader Pharmaceutical Prime Vendor Global Program that supports military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.1k | 6/9/25 |